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The establishment of a reliable prenatal source of autologous, transgene-free progenitor cells has enormous
potential in the development of regenerative-medicine-based therapies for infants born with devastating birth
defects. Here, we show that a largely CD117-negative population of human amniotic fluid mesenchymal
stromal cells (AF-MSCs) obtained from fetuses with or without prenatally diagnosed anomalies are readily
abundant and have limited baseline differentiation potential when compared with bone-marrow-derived
MSCs and other somatic cell types. Nonetheless, the AF-MSCs could be easily reprogrammed into induced
pluripotent stem cells (iPSCs) using nonintegrating Sendai viral vectors encoding for OCT4, SOX2, KLF4,
and cMYC. The iPSCs were virtually indistinguishable from human embryonic stem cells in multiple assays
and could be used to generate a relatively homogeneous population of neural progenitors, expressing PAX6,
SOX2, SOX3, Musashi-1, and PSA-NCAM, for potential use in neurologic diseases. Further, these neural
progenitors showed engraftment potential in vivo and were capable of differentiating into mature neurons and
astrocytes in vitro. This study demonstrates the usefulness of AF-MSCs as an excellent source for the
generation of human transgene-free iPSCs ideally suited for autologous perinatal regenerative medicine
applications.
Introduction
Progress in the field of autologous tissue engineeringand regenerative medicine continues to be hampered by
a general lack of reliable and abundant sources of cells. The
generation of patient-specific induced pluripotent stem
cells (iPSCs) by the forced expression of defined, trans-
gene-free reprogramming factors has the potential to pro-
vide an unlimited source of autologous cells, thereby
leading to unique opportunities to develop novel, cell-
based therapies for conditions that currently respond poorly
to conventional treatment.
To date, iPSCs have been generated by nonintegrative
techniques from numerous somatic cell types, including
dermal fibroblasts, adipocytes, and mobilized CD34 +
cells. Unfortunately, none of these cell types are readily
accessible for reprogramming for the fetus diagnosed with
a major birth defect. Many of these patients—afflicted
with a wide range of disorders, such as craniofacial mal-
formations, myelomeningocele, congenital heart disease,
congenital diaphragmatic hernia, pulmonary hypoplasia,
and structural brain abnormalities—could substantially
benefit from autologous iPSC-based technologies deliv-
ered in a timely fashion, either prenatally or in the early
postnatal period.
Somatic cells normally present within amniotic fluid,
the substance that surrounds the fetus throughout gesta-
tion, have been evaluated for decades as a diagnostic tool
to rule out major karyotypic abnormalities in fetuses
thought to be at increased risk for birth defects. However,
only recently have these cells been explored for pluri-
potency and iPSC reprogramming capabilities [1–4].
Current knowledge suggests that multiple cell types exist,
including mesenchymal stromal/stem cells (MSCs) and
amniotic fluid stem (AFS) cells [5]. Given their potentially
favorable cell reprogramming characteristics and relative
ease of isolation across a wide range of gestational ages,
we sought to generate iPSC lines derived from second-
and third-trimester human amniotic-fluid-derived mesen-
chymal stromal cells (AF-MSCs) using nonintegrating,
cytoplasmic Sendai virus (SeV). These cells were subse-
quently compared with human embryonic stem cells
(ESCs) and were selectively differentiated into various
progenitor and mature neural derivatives.
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Materials and Methods
Isolation of human AF-MSCs
Approval for this work was obtained from the Institu-
tional Review Board and the Human Pluripotent Stem Cell
Research Oversight Committee at the University of Michi-
gan (No. 38565). After written informed consent, second-
and third-trimester human amniotic fluid samples (n = 7,
range = 18–37 weeks of gestation) were retrieved during
amniocentesis or fetoscopic intervention from pregnancies
with or without fetal anomalies detected by ultrasound at
Von Voigtlander Women’s Hospital, University of Michi-
gan Health System. In addition to healthy controls (n = 2),
fetal anomalies included twin-twin transfusion syndrome
(TTTS, n = 2), cleft lip/palate (n = 1), congenital heart dis-
ease (n = 1), and congenital diaphragmatic hernia (n = 1). In
each case, a normal fetal karyotype was confirmed by our
clinical laboratory within 2 weeks after specimen procure-
ment. Cells were washed twice in PBS prior to resuspension
in mesenchymal basal medium [DMEM, 20% fetal bovine
serum (FBS), 100U/mL penicillin and 100mg/mL strepto-
mycin, and 2mM l-glutamine (Invitrogen)] and incubated at
37C with 5% humidified CO2. After 24–48 h, nonadherent
cells were removed by washing the plates with phosphate-
buffered saline, and the medium was replaced as previously
described [6]. Upon reaching 75% confluence, cells were
detached using Trypsin (Invitrogen) and seeded at a split
ratio of 1:4.
iPSC derivation
Two days before transduction, unsorted 2 · 105 AF-MSCs
isolated from four patients selected at random were placed
into six-well plates. Integration-free iPSC derivation was
performed on AF-MSCs using SeV vectors encoding for
OCT4, SOX2, KLF4, and cMYC (OSKM) at 3 · 106 CIU
(CytoTune-iPS Reprogramming Kit; Invitrogen) as pre-
viously described elsewhere for postnatal dermal fibroblasts
[7,8]. SeV is a negative sense, single-stranded RNA virus
that does not integrate into the host genome and replicates
exclusively in the cytoplasm. AF-MSCs reprogrammed us-
ing conventional four Yamanaka factor retrovirus were used
as controls. Twenty-four hours later, the medium was re-
placed with mesenchymal basal medium. At day 6, the cells
were split and placed on irradiated mouse embryonic fi-
broblast (MEF) feeder layers. All cells, including H9-ESC
controls (WiCell), were cultured in human ES conditioned
medium (GlobalStem) with 4 ng/mL of FGF-2 (Millipore).
Individual colonies derived from MSCs (AF-iPSC-SeV)
were subsequently picked and propagated on MEFs, Ma-
trigel (BD Biosciences), or PMEDSAH, a defined synthetic
matrix polymer [9]. Alkaline phosphatase staining was
performed using the AP substrate kit (Millipore) according
to manufacturer’s instructions.
Directed neural differentiation
Differentiation of iPSCs into neural progenitors was
conducted based on modifications of a protocol described
elsewhere [10]. Briefly, three different AF-iPSC-SeV lines
at passage 7 or 8 were manually cut and transferred into 60-
mm petri dishes for 4 days in human ES conditioned me-
dium without FGF-2 followed by culture in neural induc-
tion medium (DMEM/F12, GlutaMAX, NEAA, and N2;
Invitrogen) for 2 days. The resulting neurospheres were
transferred into polyornithine/laminin-coated six-well plates
(Sigma-Aldrich) to facilitate rosette formation. Individual
rosettes were manually isolated, dissected, and replated
into dishes containing neural stem cell media [Neurobasal
media, B27 (Invitrogen), NEAA, GlutaMAX, and FGF-2].
Differentiation of neural progenitors into neurons was per-
formed by culturing neural progenitors in Neurobasal media,
B27, and GlutaMAX on poly-L-ornithine– and laminin
(Sigma-Aldrich)–coated 12-well plates for up to 70 days.
Astrocyte differentiation was induced by culturing neural
progenitors in DMEM, N2, GlutaMAX, and 1% FBS for
4 weeks.
Flow cytometry
AF-MSCs between passage 3 and 5 were evaluated for
MSC characteristics based on criteria as described else-
where [11]. For flow cytometry, primary antibodies used
were phycoerythron (PE)–conjugated against CD34, CD44,
CD45, CD73, CD90, CD105, CD117, OCT4A, SOX2,
SSEA3, SSEA4, TRA-1-60, TRA-1-81, and HLA-DR (all
from BD Biosciences). Cells were fixed with 2% parafor-
maldehyde prior to evaluation of antibody staining using the
LSRII flow cytometer (BD Biosciences). Resultant data
were analyzed using FloJo software (Tree Star).
Colony-forming units
To evaluate the proliferation and clonogenic capacity of
MSCs in vitro, colony-forming unit–fibroblast (CFU-F) as-
says were performed in triplicate as previously described
[8]. Cells were seeded in serial dilution in 96-well plates
starting from an initial inoculum of 103 cells per well and
cultured in mesenchymal basal medium for 10 days, fixed
with 10% buffered paraformaldehyde, and stained with a
0.1% solution of crystal violet. The CFU-F was determined
by the number of colonies (‡ 20 cells/colony) per 100 cells
seeded.
MSC differentiation
Adipogenic, osteogenic, and chondrogenic differentiation
of MSCs was performed at passage 4 using the following
protocols [12]. For adipocyte differentiation, confluent cells
were placed in adipogenic differentiation medium [0.5mM
isobutylmethylxanthine (EMD Millipore), 200 mM indo-
methacin (MP Biomedicals), 10 - 6 M dexamethasone (MP
Biomedicals), and 10 mg/mL of insulin (Sigma-Aldrich) in
aMEM (Invitrogen)] supplemented with 10% FBS. After
21 days, control and treated cells were fixed with 10%
buffered paraformaldehyde and intracellular lipid droplets
were stained with 0.5% oil red O (Invitrogen) or using an
antibody against fatty acid binding protein-4 (FABP4;
R&D Systems). For osteoblast differentiation, confluent
cells were cultured in osteogenic differentiation medium
[10 - 7 M dexamethasone (MP Biomedicals) and 10mM
b-glycerophosphate (Alfa Aesar) in DMEM] supplemented
with 10% FBS. After 21 days, cells were fixed as earlier
and assessed for matrix mineralization by 0.6% alizarin red
S staining or an antibody against osteocalcin (OC; R&D
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Systems). For chondrocyte differentiation, cells were cultured
as micromass pellets in differentiation medium (DMEM, 10ng/
mL TGF-b, and 10-7 M dexamethasone) supplemented with
10% FBS. After 28 days, pellets were fixed with 10% buffered
paraformaldehyde, embedded in OCT compound (TissueTek),
and hexane cooled over an acetone dry-ice slurry. Ten-mi-
crometer-thick cryosections were stained with a 1% solution of
alcian blue or an antibody against aggrecan (R&D Systems).
Embryoid body assay
Embryoid bodies (EBs) were formed in suspension cul-
ture and analyzed using methods previously described [13].
Briefly, AF-iPSC-SeV colonies derived from each parental
AF-MSC were transferred into low-adherence dishes con-
taining human ES conditioned medium. After 14 days in
suspension culture, EBs were placed in 12-well plates for up
to 28 days to allow spontaneous differentiation prior to gene
expression and immunocytochemical analysis.
Reverse transcription–polymerase chain reaction
and quantitative polymerase chain reaction
Total RNA was extracted from cells using TRIzol (In-
vitrogen). First-strand cDNA was prepared with the Taqman
Reverse Transcription Reagent kit (Applied Biosciences).
Reverse transcription (RT)–polymerase chain reaction (PCR)
was performed in triplicate at 35 cycles (Life Technologies).
The primer sequences for RT-PCR can be found in Supple-
mentary Table S1 (Supplementary Data are available online at
www.liebertpub.com/scd). Quantitative PCR (qPCR) was
carried out on a Mastercycler ep realplex (Eppendorf) using
Fast SYBR Green Master Mix (Applied Biosystems) as re-
commended by manufacturer. Relative gene expression was
analyzed by qPCR with GAPDH used as a reference gene to
normalize target gene expression using the 2-DDCt method
[14]. The primer sequences used for qPCR are provided in
Supplementary Table S2.
Global gene expression analysis
To compare transcriptomes of parental cell types and plu-
ripotent stem cells, microarray analysis was performed. Total
RNA was extracted using TRIzol from one randomly selected,
Sendai-virus-reprogrammed iPSC clone and its parental AF-
MSC line at three different passages (range= 5–15). Total
RNA from dermal fibroblasts and H9-ESCs from a single
passage were used as controls. Sample processing, probing to
the Human Gene 2.1 ST array platform (Affymetrix), and data
analysis were performed by the University of Michigan DNA
Sequencing Core Microarray Facility. Normalized expression
by robust multiple-array averages was plotted using the
heatmap.2 function from the gplots package in R (www.r-
project.org) using default parameters. The euclidean distance
dissimilarity matrix and complete linkage method were used
to generate the dendrogram. Expression values range from
*1 to 12 with lower expression values shown in red and
higher expression values shown in blue.
Immunocytochemical analyses
To assay pluripotency in each established AF-iPSC-SeV
cell line, primary antibodies against NANOG (Abcam),
OCT4 (Santa Cruz), SOX2, SSEA3, SSEA4, TRA-1-60, and
TRA-1-81 (Millipore) were used following fixation in 4%
paraformaldehyde. Primary antibodies used to evaluate dif-
ferentiation were against Nestin (Millipore), Neuron-specific
class b-III tubulin (TuJ1; Covance), PSA-NCAM (Millipore),
a-fetoprotein (AFP), FOXA2, and SOX17 (R&D Systems).
Cells were examined using epifluorescence microscopy (DM
IRB; Leica).
Cytogenetics
Karyotyping was performed on AF-iPSC-SeVs and neural
progenitors derived from AF-iPSC-SeVs (AF-NPC-SeVs)
every five passages by Cell Line Genetics. Chromosome
spreads were prepared using standard protocols and mea-
surements were performed using the GTL-banding method
on 20 metaphase preparations.
Neurosurgical implantation and analysis
Cell transplantation in a neonatal rodent model was
conducted with approval of the University of Michigan
Committee on the Use and Care of Animals (No. 10447-1).
AF-NPC-SeVs were incubated with magnetic microbeads
(Miltenyi Biotec) conjugated with PSA-NCAM antibody at
4C for 10min and positively selected by cell sorting. One-
day-old Sprague-Dawley rat pups (n= 4) were anesthetized
with isoflurane. PSA-NCAM-positive cells were injected
(250,000 cells/injection in 5-mL volume of PBS) through the
sagittal suture directly into the brain parenchyma using a
stereotactic frame (David Kopf Instruments). The incision
was closed with 4-0 monocryl (Ethicon) suture. Rats were
euthanized at either 1 or 6 weeks after implantation. For
immunohistochemical analysis, all animals were transcar-
dially perfused with 10% formalin. The brains were collected
and postfixed overnight prior to cryoprotection in 30% su-
crose solution. Brains were embedded in OCT compound and
hexane cooled over an acetone dry-ice slurry. Eighteen-
micrometer-thick coronal cryosections were cut and probed
with a mouse anti-human nuclear antigen (HNA) antibody
(Millipore). Stained sections were mounted using Prolong
Gold Antifade Reagent with DAPI (Life Technologies) and
analyzed with a confocal microscope (Nikon).
Statistical analyses
Quantitative data analyses were performed in triplicate
and presented as the mean –SEM. The data were analyzed
by the Student’s t-test or analysis of variance with Bonfer-
roni correction for multiple comparisons using GraphPad
Prism software (version 5.0d). Results were considered to be
statistically significant if P £ 0.05 unless otherwise stated.
Results
Human AF-MSCs have unique phenotypic
characteristics and limited mesenchymal
differentiation potential
We isolated AF-MSCs without cell sorting from second-
and third-trimester amniotic fluid from fetuses with and
without prenatally diagnosed congenital anomalies. Within
1 week after seeding in mesenchymal basal medium, plastic
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adherent, fibroblast-appearing cells were detected in the
majority (5/7, 71.4%) of amniotic fluid samples across a
wide range of gestational ages (mean = 22.5 weeks). The
AF-MSCs grew in monolayers and displayed a relatively
homogeneous, spindle-shaped morphology after the first
passage (Fig. 1A, upper left). Their fetal origin and lack of
maternal contamination among AF-MSCs harvested from
male fetuses was confirmed by SRY and X-linked amelo-
genin qPCR assays (Fig. 1B). The AF-MSCs were clono-
genic, demonstrating a CFU-F of 0.8 colonies for every 100
cells seeded (Fig. 1A, lower left). AF-MSCs were success-
fully maintained in continuous culture for over 3 months
(passage 8) without morphologic change or evidence of
reduced cell proliferation.
To evaluate the mesodermal differentiation potential of AF-
MSCs, directed differentiation experiments were performed
and confirmed that a subset of AF-MSCs were capable of
differentiating into different mesodermal cell types, namely,
adipocytes and osteoblasts, when cultured in the appropriate
directive media for 3 weeks (Fig. 1A). Evidence of adipogenic
differentiation was indicated by the presence of oil red O-
positive lipid vacuoles within the cytoplasm of a subpopula-
tion of AF-MSCs (Fig. 1A, upper middle) and by expression
of FABP4 (Fig. 1A, lower middle) by immunofluorescence.
There was minimal osteogenic differentiation in only a subset
of AF-MSCs as evidenced by increased extracellular calcium
matrix staining in the presence of alizarin red (Fig. 1A, upper
right) and by positive expression of the late osteogenic marker
OC (Fig. 1A, lower right). However, the degree of adipogenic
and osteogenic differentiation was far less robust in AF-MSCs
compared with that observed with unsorted human bone-
marrow-derived MSCs (data not shown). Further, there was
no evidence of chondrocyte differentiation among AF-MSCs
cultured as micromass pellets under chondrogenic conditions.
Given the apparent reduced differentiation potential of
AF-MSCs and their morphologic similarities to dermal
FIG. 1. Characterization of human amniotic fluid mesenchymal stromal cells (AF-MSCs). (A) Phase-contrast photomicro-
graph illustrating typical AF-MSC morphology at passage 4 (upper left, magnification, 100· ). Representative colony forming
unit–fibroblast (CFU-F) from AF-MSCs stained with 0.1% crystal violet (lower left, magnification, 5· ). Oil red O staining of
AF-MSCs grown under adipogenic conditions for 21 days reveals orange-red cytoplasmic lipid droplets consistent with
adipocytes (upper middle, magnification, 100· ). Immunofluorescence microscopy of AF-MSCs under adipogenic conditions
demonstrates expression of adipogenic marker, fatty acid binding protein 4 (FABP4, lower middle, magnification, 100· ).
Alizarin red S staining of AF-MSCs in osteogenic conditions for 21 days shows extracellular mineral deposition (upper right,
magnification, 100· ). Immunofluorescence microscopy of AF-MSCs under osteogenic conditions demonstrates expression of
osteogenic marker, osteocalcin (OC, lower right, magnification, 100· ). (B) SRY (upper) and amelogenin (lower) gene
expression among isolated AF-MSCs by representative quantitative polymerase chain reaction (qPCR). Absence of SRY in a
female fetal sample (MSC2) and upregulation of SRY in male fetal samples (MSC1 and MSC3) comparable to foreskin dermal-
fibroblast-positive control. Upregulation of X-linked amelogenin (AMELX) in a female fetal sample (MSC2) compared with
male fetal samples (MSC1 and MSC3) and foreskin dermal fibroblasts. (C) Global gene expression patterns of AF-MSCs were
compared with those of neonatal dermal fibroblasts analyzed using regression analyses. R2 denotes the coefficient of deter-
mination. (D) Flow cytometry characterization of AF-MSCs (positive shown in red compared with blue negative control) at
passage 4 grown in mesenchymal basal media, suggesting a unique immunophenotypic profile with positive staining for MSC
markers (CD44, CD73, CD90, and CD105) and selected pluripotency markers (SSEA3 and SSEA4). AF-MSCs do not stain for
the hematopoietic marker (CD34), CD117, or the class II major histocompatibility complex antigen HLA-DR. (E) Immuno-
fluorescence microscopy of AF-MSCs merged with DAPI (in blue) showing lack of NANOG expression but expression of
SSEA3, SSEA4, and TRA-1-60 (magnification, 100· ). Color images available online at www.liebertpub.com/scd
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fibroblasts, we next sought to determine whether AF-MSCs
were similar to fully differentiated dermal fibroblasts, the
most common postnatal parental cell type used for repro-
gramming toward pluripotency. Using a microarray re-
presenting the genome-wide transcriptome and regression
analysis, the global gene expression profile of primary AF-
MSCs was different from that of the neonatal dermal fi-
broblast cell line (R2 = 0.87, Fig. 1C).
The immunophenotypic profile of unsorted AF-MSCs was
further characterized by flow cytometry. AF-MSCs uni-
formly expressed surface epitope markers associated with
bone-marrow-derived MSCs (Fig. 1D), including CD44
(mean= 96.7% of cells), CD73 (95.7%), CD90 (88.9%), and
CD105 (83.4%). In contrast, less than one percent of cells
expressed HLA-DR or hematopoietic stem cell markers,
including CD34 and CD45 (data not shown). Although the
pluripotency marker NANOG was not detected (data not
shown), 62.8% and 66.8% of cells displayed SSEA3 and
SSEA4, respectively (Fig. 1D). The percentage of AF-MSCs
that expressed CD117 was either very low or undetectable in
all samples (mean= 0.66%). To further support the unique,
mixed phenotypic signature of AF-MSCs, we performed
immunofluorescence staining, which showed lack of NA-
NOG expression but positive expression of SSEA3 and
SSEA4, and in some established primary AF-MSCs, TRA-1-
60 (Fig. 1E).
AF-MSCs can be readily reprogrammed
into transgene-free pluripotent cells
Successful OSKM reprogramming of unsorted AF-MSCs
(n= 4) with the nonintegrating SeV was observed when
cultured under standard ESC conditions. AF-MSCs began to
aggregate while reducing cytoplasmic volume and losing
their spindle-shaped morphology between 14 and 21 days in
culture (Fig. 2A, left). At 28 days, there were multiple-
candidate iPSC colonies with well-defined borders and high
nuclear-to-cytoplasm ratios analogous to undifferentiated
H9-ESCs. We confirmed that AF-iPSC-SeVs expressed high
levels of alkaline phosphatase (Fig. 2A, right). Using
FIG. 2. Characterization of human induced pluripotent stem cells (iPSCs) derived from amniotic fluid (AF) mesenchymal
stromal cells. (A) Representative colony morphology of AF-iPSCs using nonintegrating Sendai virus (SeV) grown on mouse
embryonic feeders at day 18 (left, magnification, 100 · ). Large AF-iPSC-SeV colony with evidence of pluripotency by
alkaline phosphatase (AP) staining (right, magnification, 20 · ). (B) Representative karyotype analysis of AF-iPSC-SeV
colonies based on 20 G-banded metaphase cells demonstrating normal chromosomes (passage 18). (C) Immunofluorescence
photomicrographs of AF cells reprogrammed with SeV (AF-iPSC-SeV, upper), AF cells reprogrammed with retrovirus (AF-
iPSC-Retro, middle), and H9-ESC controls (lower) on mouse feeder layers, demonstrating expression of the following
pluripotency markers: NANOG, OCT4, SOX2, SSEA3, TRA-1-60, and TRA-1-81 (magnification, 20· ). DAPI staining in
blue. Color images available online at www.liebertpub.com/scd
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OSKM SeV, the overall reprogramming efficiency of AF-
MSCs into iPSCs ranged from 0.01% to 0.05% and was
comparable to the efficiency seen using AF-MSCs with
OSKM retrovirus (AF-iPSC-Retro).
A total of 10 different AF-iPSC-SeV lines were suc-
cessfully transferred onto feeder-free systems, including
either Matrigel- or PMEDSAH-coated dishes, for further
expansion, subculture, and additional characterization.
There were no major differences in morphology based on
these different culture conditions. Cytogenetic analyses
showed normal karyotypes, indicating that AF-iPSC-SeVs
remained free of nonclonal aberrations after continuous
in vitro expansion to passage 20 (Fig. 2B). Immunofluo-
rescence staining revealed uniformly high expression of
NANOG, OCT4, SOX2, SSEA3, SSEA4, TRA-1-60, and
TRA-1-81 within AF-iPSC-SeV colonies in a pattern
similar to that seen with AF-iPSC-Retro and H9-ESC
colonies (Fig. 2C).
Qualitative gene expression analyses of different AF-
iPSC-SeV clones demonstrated upregulation of key plur-
ipotency genes, including NANOG and SOX2, compared
with low levels observed with parental primary AF-MSCs
(Fig. 3A). There was endogenous expression of OCT4
among all AF-MSCs that were maintained following re-
programming. Loss of a-smooth muscle actin (a-SMA)
amplification normally present in AF-MSCs was seen fol-
lowing conversion to AF-iPSC-SeVs (data not shown).
Evidence for genomic integration of SeV vectors was
evaluated by RT-PCR. From passage 6 onward, the SeV
transgene was nearly undetectable but strong expression of
NANOG among AF-iPSC-SeV clones remained (Fig. 3B).
Complete absence of SeV transgene expression in the
presence of NANOG amplification was noted by passage 10.
In accordance with the RT-PCR results, quantitative gene
expression studies of AF-iPSC-SeVs showed significant
upregulation in NANOG compared with parental AF-MSCs
(P £ 0.05, Fig. 3C). There was a similar significant increase
in SOX2 and KLF4 among AF-iPSC-SeVs comparable to
levels observed in H9-ESCs. Despite high endogenous ex-
pression of OCT4 among AF-MSCs shown by RT-PCR,
qPCR revealed significant increases in OCT4 transcripts
after SeV reprogramming when normalized for baseline
GAPDH expression (P £ 0.05). There was a significant de-
crease in cMYC amplification in AF-iPSC-SeVs compared
FIG. 3. Gene expression of representative human amniotic-fluid-derived iPSCs reprogrammed with nonintegrating Sendai
virus. (A) Reverse transcription (RT)-PCR of iPSC RNAs showing maintenance of OCT4 and upregulation of NANOG and
SOX2. (B) Representative RT-PCR from an AF-iPSC-SeV clone demonstrating maintenance of NANOG but loss of the SeV
transgene sequences by passage 6 (P6). (C) Quantitative analysis by qPCR demonstrating marked upregulation of selected
pluripotency genes, including NANOG, OCT4, SOX2, and KLF4, among AF-iPSC-SeVs (n= 3) to levels comparable to that
of H9-ESCs. Data were normalized relative to dermal fibroblast controls and presented as the mean–SEM (n= 5, *P£ 0.05).
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with AF-MSCs (P £ 0.05), but no significant difference in
TERT expression.
Global gene expression of AF-iPSC-SeVs
is similar to that of ESCs
To determine the similarities and differences of AF-
iPSC-SeVs versus ESCs, we compared an AF-iPSC-SeV
clone at three different passages to parental AF-MSCs and
H9-ESCs in a microarray representing the genome-wide
transcriptome. The dendrogram of one-way unsupervised
hierarchical clustering analysis demonstrated that AF-
iPSC-SeV clones clustered with H9-ESCs, distinct from a
cluster containing parental AF-MSCs and dermal fibro-
blasts (Fig. 4A). To assess the similarities and differences
between the various cell types in more detail, a heatmap of
5,285 upregulated and downregulated genes was generated,
which revealed transcriptome patterns in AF-iPSC-SeVs
that were nearly identical to H9-ESCs (Fig. 4B). In ac-
cordance with the qPCR data, focused analysis of key
pluripotency genes, including NANOG, OCT4, SOX2,
LIN28, DPPA2, and FGF4, showed no significant differ-
ences between AF-iPSC-SeVs and H9-ESCs. In contrast,
with the exception of KLF4, there was significant upre-
gulation of pluripotency-associated genes in AF-iPSC-SeV
clones when compared with primary AF-MSCs (data not
shown, P < 0.001). Finally, global gene expression patterns
of AF-iPSC-SeVs were nearly identical to those of H9-
ESCs (R2 = 0.97) and divergent from those of parental AF-
MSCs (R2 = 0.86, Fig. 4C).
FIG. 4. Global gene expression analysis of amniotic-fluid-derived iPSCs using Sendai virus. (A) Dendrogram shows the
unsupervised hierarchal clustering of AF-iPSC-SeVs, and parental AF-MSCs (both analyzed at three different passages)
compared with dermal fibroblast and H9-ESC controls. (B) Heatmap reveals the relationship of 5,285 genes differentially
expressed by H9-ESCs, AF-iPSC-SeVs, AF-MSCs, and dermal fibroblasts. Higher and lower levels of transcripts are shown
in blue and red, respectively. The transcriptome patterns expressed by AF-iPSC-SeVs were nearly identical to those
expressed by H9-ESCs (far left). (C) Global gene expression patterns of AF-iPSC-SeVs were more closely correlated with
patterns observed in H9-ESCs (right) compared with those from parental primary cell lines (AF-MSCs, left). R2 denotes the
coefficient of determination. Color images available online at www.liebertpub.com/scd
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AF-iPSC-SeVs are capable of spontaneous
three-germ layer differentiation in vitro
In an effort to determine whether AF-iPSC-SeVs were
pluripotent in vitro, iPSC clones derived from three different
AF-MSC samples were allowed to spontaneously differen-
tiate in low-adherence cultures as EBs. Whereas AF-MSCs
had neither the ability to form EBs nor the capability of
surviving in suspension culture, AF-iPSC-SeVs exhibited
robust EB formation after 7 days in suspension culture.
Between 21 and 28 days, cells attached and adopted a flat-
tened morphology at the periphery. Further, immunocyto-
chemical analysis of AF-iPSC-SeV-EBs confirmed the
presence of derivatives of three germ layers similar to EBs
generated from retroviral-reprogrammed AF-MSCs (Fig.
5A). AF-iPSC-SeV-EBs expressed for endoderm markers,
including AFP, SOX17, and FOXA2 (Fig. 5A, right). Me-
sodermal differentiation was confirmed by the presence of
a-SMA, and ectodermal differentiation was shown by pos-
itive Nestin and TuJ1 expression. Similarly, RT-PCR ana-
lyses of RNAs from EBs derived from AF-iPSCs-SeVs
demonstrated successful differentiation into endodermal
cells by AFP and GATA4 expression, into mesodermal cells
by a-SMA, DCN, and RUNX1 expression, and into ecto-
dermal cells by Nestin and TuJ1 expression (Fig. 5B).
SeV-reprogrammed AF-MSCs can differentiate
into neural progenitors
To test whether transcription-factor-free, amniotic-fluid-
derived iPSCs could be differentiated into early neural lin-
eages, AF-iPSC-SeVs at passage 8 were exposed to neural
differentiation culture conditions. Neurospheres attached
and formed neural rosettes typical of neuroepithelial cells
within 7 days of adherent culture (Fig. 6A, left). These
neural progenitor colonies were subsequently detached,
expanded, and analyzed at passage 8. In this neurogenic
environment, these morphologically distinct cells no longer
expressed NANOG and OCT4 by immunofluorescence (Fig.
6A). Further, they expressed multiple early neural markers,
including SOX2, SOX3, PAX6, Nestin, MSI1, and PSA-
NCAM (Fig. 6B). With the exception of SOX2, undiffer-
entiated AF-iPSC-SeVs did not express these neural
progenitor markers (data not shown). Evaluation of cell sur-
face marker epitopes by flow cytometry confirmed the in-
creased expression of PSA-NCAM and decreased expression
of SSEA4 following directed differentiation of AF-iPSC-
SeVs into the early neural lineage (Fig. 6C). The mean per-
centage of PSA-NCAM-positive cells increased from 3% to
53% whereas SSEA3- and SSEA4-positive cells decreased to
0.8% and 0.1%, respectively. RT-PCR analyses of neural
progenitor cells differentiated from AF-NPC-SeVs down-
regulated NANOG and OCT4 and upregulated the neural
progenitor transcription factors SOX1 and PAX6 (Fig. 6D).
Karyotype analysis of AF-NPC-SeVs performed between
passage 5 and 8 demonstrated normal chromosomes based on
20 G-banded metaphase cells. The only nonclonal aberration
detected was trisomy 12, an abnormality that is generally
identified at a frequency of 2.5%.
To confirm the ability of human AF-NPC-SeVs to suc-
cessfully engraft into the central nervous system in vivo,
PSA-NCAM-positive cells were injected into the cerebrum
of neonatal rats. Despite xenotransplantation of donor cells
into an immunocompetent host, histologic analyses showed
survival of the AF-NPC-SeVs when examined 8 days after
injection. An abundant signal of HNA-positive cells was
readily identified adjacent to the delivery site in both ani-
mals but not in the adjacent native brain parenchyma (Fig.
6E). Six weeks after injection, there was no convincing
evidence of HNA-positive cells in evaluated animals (data
not shown).
Neural progenitors can differentiate into neuronal
and glial progeny in vitro
To verify the multilineage differentiation capacity of AF-
NPC-SeVs, we performed directed in vitro experiments
FIG. 5. Representative embryoid body (EB) formation of amniotic-fluid-derived iPSCs using Sendai virus. (A) Im-
munofluorescence microscopy of EBs from iPSCs reprogrammed with Sendai virus (AF-iPSC1-SeV) and retrovirus (AF-
iPSC-Retro) merged with DAPI (in blue) showing expression of TuJ1 (ectoderm), a-smooth muscle actin (a-SMA) (me-
soderm), and FOXA2 (endoderm, magnification, 20 · ). Similar three germ layer expression was also seen among EBs from
H9-ESCs (data not shown). (B) RT-PCR from AF-iPSC-SeV-EB RNA extracted at 28 days, demonstrating activation of
endodermal, mesodermal, and ectodermal genes. Color images available online at www.liebertpub.com/scd
2620 JIANG ET AL.
aimed at differentiation into both neuronal and glial phe-
notypes. AF-NPC-SeVs maintained in neurogenic media for
up to 2 months were capable of efficient differentiation into
neurons. Phase-contrast microscopy showed characteristic
morphological changes including cells with extension of
neurites as early as 12 days after induction (Fig. 7A, upper
left). Immunofluorescence staining revealed robust expres-
sion of the early neuronal marker doublecortin (DCX) as
well as more mature neuronal markers, including TuJ1 and
MAP2 (Fig. 7A). Loss of PAX6 amplification and increased
amplification of MAP2 was observed by RT-PCR (data not
shown). There was some degree of nonspecific neural dif-
ferentiation evidenced by the expression of GFAP but not
Olig2 following neuronal induction (data not shown).
To determine whether AF-NPC-SeVs were capable of
differentiating toward a glial fate, AF-NPC-SeVs main-
tained in neural induction media were switched to astrocyte
media for 4 weeks. Over the ensuing weeks, the majority of
cells adopted a stellate morphology. Robust astrocyte dif-
ferentiation was evidenced by marked upregulation of
GFAP but not Olig2 by RT-PCR (Fig. 7B). Following as-
trocyte induction, nestin and MSI1 amplification was still
expressed but at reduced levels. Evidence for the continued
presence of neuronal dendrites was supported by ongoing
FIG. 6. Directed differentiation of AF-iPSC-SeVs into neural progenitor cells (AF-NPC-SeV) in vitro. (A) Photo-
micrograph of typical neural rosette formation under phase-contrast microscopy (upper left, magnification, 20· ), and
morphology of representative neural stem cells at several passages under phase microscopy (NSCs) (upper right, magni-
fication, 100 · ). Merged photomicrographs showing lack of expression of two pluripotency markers, NANOG (lower left,
magnification, 100 · ) and OCT4 (lower right, magnification, 40 · ). DAPI in blue. (B) Merged photomicrographs showing
staining for early neural markers (magnification, 40 · ), including SOX2 (red, upper left), SOX3 (red, upper middle), PAX6
(green, upper right), Nestin (green, lower left), Musashi-1 (MS1, red, lower middle), and PSA-NCAM (red, lower right).
DAPI in blue. (C) Flow cytometry characterization of representative AF-NPC-SeVs (positive shown in blue compared with
red negative control without antibody) at passage 5 demonstrating expression of the neural progenitor cell surface marker
PSA-NCAM and lack of staining of the pluripotency marker SSEA4. (D) Representative RT-PCR showing loss of NANOG
and OCT4 expression but gain in SOX1 and PAX6 expression after directed differentiation to neural progenitors (AF-NPC-
SeV). (E) Representative karyotype analysis of AF-NPC-SeVs based on 20 G-banded metaphase cells demonstrating
normal chromosomes (passage 8). (F) Eight days after transplantation of AF-NPC-SeVs into the brain parenchyma of
neonatal rats, evidence for engraftment is demonstrated by immunoreactivity to human nuclear antigen (HNA, red) anti-
bodies. Shown are representative merged photomicrographs magnified at 20 · (left), 100 · (center), and 100· confocal
(right). DAPI in blue. Color images available online at www.liebertpub.com/scd
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transcription of MAP2. Immunofluorescence staining showed
the increased presence of GFAP-positive cells that were not
normally expressed by AF-NPC-SeVs and more mature
neuronal cells. There were scattered, rare areas showing
TuJ1-positive cells (Fig. 7C). Olig2 expression was uniformly
low, confirming that the glial lineage differentiation of
transgene-free neural progenitors was directed toward an
astrocytic phenotype.
Discussion
While postnatal dermal fibroblasts will likely remain the
somatic cell of choice for basic research to mechanistically
dissect most cellular reprogramming processes, iPSC deri-
vation for therapeutic purposes will ultimately require that
the candidate parental population to be readily accessible,
easy to reprogram, and free from genetic aberrations [15].
For the fetus with a prenatally diagnosed anomaly amend-
able to cell transplantation, AF-MSCs would be ideal for
facilitating early and effective stem cell therapy. At 28
weeks of gestation, from a mean volume of amniotic fluid of
800mL, a 10mL aliquot of fluid obtained under ultrasound
guidance could yield a large starting population of AF-
MSCs within several weeks. Moreover, an amniocentesis
would avoid the inherent risk of fetal injury and/or demise
associated with fetal skin biopsy.
In this report, we successfully derive new human
transgene-free iPSC lines from AF-MSCs isolated from
second- and third-trimester amniotic fluid. The resultant
iPSCs were virtually indistinguishable from H9-ESCs in
multiple assays and, in support of this therapeutic concept,
could be used to generate a relatively homogeneous popu-
lation of neural progenitors, expressing PAX6, SOX2,
SOX3, MSI1, and PSA-NCAM. Further, these neural pro-
genitors were capable of differentiating into mature neurons
and astrocytes in vitro and showed transient engraftment
potential after implantation in a xenogeneic model. Based
on the existing protocols employed in this study, a purified
population of neural progenitors could be generated from a
small aliquot of amniotic fluid in as little as 8 weeks. The
reprogramming efficiency of AF-MSCs with nonintegrating
SeV in our study is comparable to reports using integrative
techniques on cells derived from other extraembryonic tis-
sue sources, including placenta, Wharton’s jelly, and am-
niotic membrane [2,16,17].
By definition, the AF-MSCs in this study were adherent to
plastic in culture, had defined immunophenotypic charac-
teristics, and possessed limited differentiation capabilities
[11]. To our knowledge, only one other report has suc-
cessfully described iPSC reprogramming of AF-MSCs using
nonintegrating techniques. In that study, an excisable cas-
sette based on Cre/LoxP technology was employed to
FIG. 7. Characterization of neural progenitors from human amniotic-fluid-derived iPSCs in vitro. (A) Morphology of
AF-NPC-SeVs after directed differentiation into the neuronal lineage viewed under phase microscopy at day 12 (upper
left, magnification, 100 · ). Merged photomicrographs at day 70 showing immunofluorescence for several neuronal
markers (magnification, 40 · ), including doublecortin (DCX, purple, upper right), neuron-specific class III b-tubulin
(TuJ1, green, lower left), and microtubule-associated protein-2 (MAP2, green, lower right). DAPI in blue. (B) RT-PCR
exhibiting gain in glial fibrillary acid protein (GFAP) expression after directed differentiation of neural progenitors (AF-
NPC1-Sev) toward the astrocyte (AF-Astr1-SeV) lineage. (C) Merged photomicrographs (magnification, 40 · ) after
directed differentiation of AF-NPC1-SeV toward astrocytes, demonstrating immunofluorescence staining of selected
cells for GFAP (left) and TuJ1 (middle) but not Olig2 (right), superimposed with blue DAPI. Color images available
online at www.liebertpub.com/scd
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generate iPSCs from a fetus with thalassemia [18]. Although
this technique is relatively efficient, an *200-bp fragment
of inactive viral LTR remains in the host genome after an
inherently labor-intensive process involving the identifica-
tion of clones with vector integration. Further, directed
differentiation of integration-free iPSCs derived from am-
niocytes into a homogeneous and clinically relevant cell
type has not been reported.
More recently, Guillot and colleagues elegantly demon-
strated a transgene-free approach employing the histone
deacetylase inhibitor valproic acid to induce pluripotency
from amniotic fluid cells [19]. A key distinction in this study,
however, is the use of CD117-positive AFS cells, a clonal
population of somatic cells that requires magnetic bead
sorting to identify these rare (< 1%) amniocytes, followed by
months of in vitro culture. Hierarchical clustering data
showed that the valproic-acid-exposed AFS cells are more
closely related to native AFS cells than to H9-ESCs. Further,
the use of AFS-cell-based therapies for autologous purposes
may be difficult since it remains unclear whether these
CD117-positive cells are present in every specimen, and
particularly in those beyond 22 weeks of gestation, the time
period when many prenatal anomalies are initially charac-
terized by maternal-fetal medicine clinicians with ultrasound
imaging [20,21]. By the third trimester of pregnancy, the
pluripotency of fetal cells derived from other extraembryonic
tissues also seems to become more restricted [1].
Purified populations of neural cells derived from transgene-
free AF-iPSCs in vitro may facilitate the development of
tissue engineering and other cell-based therapies for some of
the most difficult perinatal disorders treated in neonatal in-
tensive care units worldwide [22]. Specific neurological
diseases, all of which are manifested by damage or loss of
organ function, would include neonatal hypoxic-ischemic
encephalopathy, cerebral palsy, myelomeningocele, and struc-
tural brain malformations. In our study, neural progenitors
were generated from one recipient fetus with TTTS, a con-
dition associated with a sevenfold increased risk of long-term
neurologic morbidity secondary to antenatal cerebral hypo-
perfusion in the donor twin with hyperviscosity and polycy-
themia in the recipient twin [23]. Other neonates who might
also benefit fromAF-iPSC-based therapies include those with
significant nongenetic prenatal abnormalities involving the
heart, lungs, and liver.
The use of AF-MSCs as a substrate for transgene-free
iPSC reprogramming offers many other potential advan-
tages in regenerative medicine beyond the perinatal period.
Recent work has shown that reprogrammed cells at early
passages have varied differentiation potential and residual
DNA methylation signatures that are biased toward their
original cell phenotype, commonly referred to as tissue-
specific ‘‘epigenetic memory’’ [24,25]. It would therefore be
ideal to use somatic cells with an immature ground state,
such as those originating from fetal-derived tissues, to ef-
ficiently generate fully competent iPSCs amendable for
subsequent differentiation into the target cell of choice.
Because of the embryonic/fetal origins of AF-MSCs, these
cells are believed to have an intermediate phenotype be-
tween that of true pluripotent stem cells and adult somatic
stromal cells [26,27].
Whereas the delivery of autologous cells based on AF-
iPSCs might be appealing and may prove more practical for
certain regenerative medicine applications, allogeneic trans-
plantation using cryopreserved cells derived from human
leukocyte antigen (HLA)–matched AF-iPSCs stored within
good manufacturing practice biorepositories represents an-
other viable alternative. An allogeneic approach would con-
ceivably offer some additional advantages, enabling the use of
HLA-matched cells ‘‘off-the-shelf’’ without the need for im-
munosuppression, might also be feasible in this setting given
the known immunoregulatory properties of amnion-derived
MSCs within the host environment [27–29].
Our finding of the increased ‘‘stemness’’ of AF-MSCs
based on pluripotency markers parallels the work of others
and suggests similar transcriptional and epigenetic states
compared with ESCs as well as enhanced reprogramming
capabilities [30–33]. Evidence to further support these
concepts include maintenance of long, stable telomeres in
culture and high reprogramming efficiencies among iPSCs
created using integrating ectopic factors. Recent data also
suggest that these cells have a complex molecular signature,
coexpressing trophoblastic, ectodermal, mesodermal, and
endodermal cell-type-specific regulators [34]. All of these
characteristics lend support to the potential benefits of
banking amniotic fluid for future, patient-specific thera-
peutic applications later in childhood and adult life.
Because of the relatively high expression of selected
pluripotency markers among AF-MSCs, there may be a un-
ique subset of cells within a heterogeneous population that
have even better reprogramming efficiency using SeV or
other nonintegrating techniques. The identification of certain
amniocyte subpopulations with enhanced reprogramming
ability may also allow direct reprogramming into other cell
types as was recently demonstrated [35]. The use of
fewer Yamanaka reprogramming transgenes to achieve
pluripotency within human amniocytes has also been shown
[36]. Our work will likely stimulate further research com-
paring iPSCs derived from different human fetal sources in an
effort to better understand the phenomenon of pluripotency
and tissue-specific epigenetic memory, both in vitro and
in vivo.
While we did not formally compare AF-MSC character-
istics based on the presence or absence of a fetal anomaly,
we speculate that any differences in reprogramming char-
acteristics or neural progenitor differentiation based on
prenatal diagnosis are likely to be minimal. In this study, we
also did not attempt to differentiate the AF-MSCs into
various germ layer derivatives in the absence of repro-
gramming with SeV. Consistent with findings from another
study [29], our data on somatic cells derived from amniotic
tissues suggest that they have a restricted differentiation
potential at baseline, as shown by minimal osteogenic and
chondrogenic behavior when compared with bone-marrow-
derived MSCs. The general consensus based on our past
experience, among others, has been that AF-MSCs are not
fully pluripotent since they do not generally form EBs in
low-attachment dishes. As a result, we could not readily
differentiate these cells toward the neural lineage based on
existing protocols. Some groups have shown upregulation of
neural-specific genes among AF-MSCs under specific cul-
ture conditions [37], but compelling evidence for the dif-
ferentiation of neural progenitors from truly multipotent
stem cells as opposed to committed precursor cells has not
been clearly demonstrated [38].
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In conclusion, the present study demonstrates that human
AF-MSCs from a wide range of gestational ages and pre-
natal conditions can be reliably isolated and induced into
iPSCs and neural progenitors free of reprogramming factors
using SeV. Perinatal animal experiments in the laboratory
that utilizes the derivatives of these iPSCs remain ongoing
and will hopefully facilitate the eventual development of
therapeutic-grade iPSCs for fetuses and young children with
debilitating diseases.
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